Regen BioPharma, Inc. (OTCMKTS:RGBP – Get Free Report) was the target of a significant drop in short interest in the month of June. As of June 30th, there was short interest totaling 210,000 shares, a drop of 88.7% from the June 15th total of 1,854,604 shares. Based on an average daily trading volume, of 22,065,408 shares, the short-interest ratio is currently 0.0 days.
Regen BioPharma Stock Performance
Regen BioPharma has a 1-year low of $0.00 and a 1-year high of $0.12.
About Regen BioPharma
Regen BioPharma, Inc is a development‐stage biotechnology company focused on advancing regenerative medicine and immunotherapy products through stem cell science. The company’s research efforts center on identifying and developing novel therapeutic candidates that harness the regenerative potential of adult and embryonic stem cells, with an emphasis on cancer, infectious and autoimmune diseases.
Its primary activities include the discovery and preclinical validation of stem cell‐derived receptors and peptides, the development of immuno‐oncology assets, and the filing of investigational new drug (IND) applications to support first‐in‐human studies.
See Also
- Five stocks we like better than Regen BioPharma
- Starbucks Builds Sovereign AI to Cut $400 Million in Software Costs
- Power Struggle: Wolfspeed Sues Navitas Over AI Chips
- Why WD-40 Is Proving Great Businesses Never Go Out of Style
- Pushing the Edge: Super Micro Computer Reboots the AI Landscape
Receive News & Ratings for Regen BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regen BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
